Effect of antiplatelet agents, statins, and other drugs on vascular access patency rates

Angiology

Volumn 63, Issue 1, 2012, Pages 5-8

  Paraskevas, Kosmas I ^a   Mikhailidis, Dimitri P ^b   Roussas, Nikolaos ^c   Giannoukas, Athanasios D ^c  

^a RED CROSS HOSPITAL   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EZETIMIBE PLUS SIMVASTATIN; FISH OIL; FOLIC ACID; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; OMEGA 3 FATTY ACID; PLACEBO; TICLOPIDINE; WARFARIN;

ARTERIOVENOUS FISTULA; BLEEDING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; END STAGE LIVER DISEASE; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; REVIEW; RISK; RISK REDUCTION; THROMBOSIS; TREATMENT OUTCOME; UNITED STATES; VASCULAR ACCESS; VASCULAR PATENCY;

ANTICOAGULANTS; ARTERIOVENOUS FISTULA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; VASCULAR GRAFTING; VASCULAR PATENCY;

EID: 82955201702     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711414177     Document Type: Review

References (43)

1. Woods JD, Port FK. The impact of vascular access for haemodialysis on patient morbidity and mortality. Nephrol Dial Transplant. 1997 ; 12 (4). 657-659 (Pubitemid 27170415)
2. Andrassy K, Malluche H, Bornefeld H, et al. Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid. Results of a prospective double blind study. Klin Wochenschr. 1974 ; 52 (7). 348-349
3. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2002 ; 40 (6). 1255-1263 (Pubitemid 35403138)
4. Windus DW, Santoro SA, Atkinson R, Royal HD. Effects of antiplatelet drugs on dialysis-associated platelet deposition in polytetrafluoroethylene grafts. Am J Kidney Dis. 1997 ; 29 (4). 560-564 (Pubitemid 27155277)
5. Ghorbani A, Aalamshah M, Shahbazian H, Ehsanpour A, Aref A. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian J Nephrol. 2009 ; 19 (2). 57-61
6. Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008 ; 299 (18). 2164-2171 (Pubitemid 351679707)
7. Grontoft KC, Larsson R, Mulec H, Weiss LG, Dickinson JP. Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scand J Urol Nephrol. 1998 ; 32 (4). 276-283 (Pubitemid 28387180)
8. Yevzlin AS, Conley EL, Sanchez RJ, Young HN, Becker BN. Vascular access outcomes and medication use: a USRDS study. Semin Dial. 2006 ; 19 (6). 535-539 (Pubitemid 44736562)
9. Hasegawa T, Elder SJ, Bragg-Gresham JL, et al. Consistent aspirin use is associated with improved arteriovenous fistula survival among incident hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol. 2008 ; 3 (5). 1373-1378
10. Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001 ; 37 (5). 970-980 (Pubitemid 32436569)
11. Grosser N, Schroder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol. 2003 ; 23 (8). 1345-1351 (Pubitemid 36994520)
12. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999 ; 100 (8). 793-798 (Pubitemid 29398875)
13. Kaufman JS, O'Connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003 ; 14 (9). 2313-2321 (Pubitemid 37052378)
14. Dixon BS, Beck GJ, Vasquez MA, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med. 2009 ; 360 (21). 2191-2201
15. Osborn G, Escofet X, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 2008 ; 4: CD002786
16. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998 ; 9 (12)(suppl). S16 - S23
17. Maitra S, Sekercioglu N, Baloch S, Cook WL, Jassal SV. Causes of death in older peritoneal dialysis patients-can we depend on registry reports?. Int Urol Nephrol. 2007 ; 39 (1). 345-350 (Pubitemid 46722986)
18. Soubassi LP, Chiras TC, Papadakis ED, et al. Incidence and risk factors of coronary heart disease in elderly patients on chronic hemodialysis. Int Urol Nephrol. 2006 ; 38 (3-4). 795-800 (Pubitemid 46336044)
19. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005 ; 45 (4)(suppl 3). S1 - S153
20. Paraskevas KI, Stathopoulos V, Mikhailidis DP. Pleiotropic effects of statins: implications for a wide range of disease. Curr Vasc Pharmacol. 2008 ; 6 (4). 237-239
21. Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des. 2007 ; 13 (35). 3622-3636 (Pubitemid 350238933)
22. Paraskevas KI, Giannoukas AD, Mikhailidis DP. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg. 2009 ; 23 (5). 690-699
23. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?. Eur J Vasc Endovasc Surg. 2006 ; 32 (3). 286-293 (Pubitemid 44207905)
24. Paraskevas KI, Athyros VG, Briana DD, Kakafika A, Karagiannis A, Mikhailidis DP. Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets. 2007 ; 8 (8). 942-951
25. Porter KE, Turner NA. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans. 2002 ; 30 (2). 120-126
26. Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg. 2002 ; 36 (1). 150-157 (Pubitemid 41122904)
27. Henke P, Blackburn S, Proctor MC, et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg. 2004 ; 39 (2). 357-365 (Pubitemid 38174318)
28. Abbruzzese TA, Havens J, Belkin M, et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg. 2004 ; 39 (6). 1178-1185 (Pubitemid 38952583)
29. Righetti M, Ferrario G, Serbelloni P, Milani S, Tommasi A. Some old drugs improve late primary patency rate of native arteriovenous fistulas in hemodialysis patients. Ann Vasc Surg. 2009 ; 23 (4). 491-497
30. Pisoni R, Barker-Finkel J, Allo M. Statin therapy is not associated with improved vascular access outcomes. Clin J Am Soc Nephrol. 2010 ; 5 (8). 1447-1450
31. Chou CY, Kuo HL, Yung YF, Liu YL, Huang CC. C-reactive protein predicts vascular access thrombosis in hemodialysis patients. Blood Purif. 2006 ; 24 (4). 342-346
32. Paraskevas KI, Mikhailidis DP. C-reactive protein (CRP): more than just an innocent bystander?. Curr Med Res Opin. 2008 ; 24 (1). 75-78 (Pubitemid 351160240)
33. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin. 2003 ; 19 (6). 540-556 (Pubitemid 37122048)
34. Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin. 2006 ; 22 (6). 1123-1131 (Pubitemid 44000732)
35. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study. Curr Med Res Opin. 2006 ; 22 (5). 873-883 (Pubitemid 43875555)
36. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006 ; 24 (1). 33-50 (Pubitemid 46722293)
37. Andreucci VE, Fissell RB, Bragg-Gresham JL, et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis. 2004 ; 44 (5)(suppl 2). 61-67
38. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005 ; 353 (3). 238-248 (Pubitemid 41058323)
39. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009 ; 360 (14). 1395-1407
40. Study of Heart And Renal Protection (SHARP). http://www.ctsu.ox.ac.uk/ sharp/. Accessed on February 8, 2011.
41. Sharathkumar A, Hirschl R, Pipe S, Crandell C, Adams B, Lin JJ. Primary thromboprophylaxis with heparins for arteriovenous fistula failure in pediatric patients. J Vasc Access. 2007 ; 8 (4). 235-244 (Pubitemid 351266036)
42. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol. 2002 ; 13 (1). 184-190 (Pubitemid 34042026)
43. Irish A, Dogra G, Mori T, et al. Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrol. 2009 ; 10: 1